Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingGlobeNewsWire • 04/09/24
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingGlobeNewsWire • 03/05/24
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024GlobeNewsWire • 02/15/24
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsGlobeNewsWire • 11/01/23
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International ConferenceGlobeNewsWire • 10/14/23
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to BuyZacks Investment Research • 10/04/23
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberGlobeNewsWire • 08/29/23
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/03/23
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations UpdateGlobeNewsWire • 05/08/23
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in MayGlobeNewsWire • 04/27/23
Prelude Therapeutics to Present at American Association for Cancer Research 2023 ConferenceGlobeNewsWire • 04/11/23
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/15/23
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic CancersGlobeNewsWire • 03/15/23
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor ConferencesGlobeNewsWire • 02/09/23
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/22
Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?Zacks Investment Research • 08/10/22
Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 08/09/22
Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should KnowZacks Investment Research • 06/22/22